Klinischer Newsletter
Für regelmmäßige Updates zu unseren neusten Studien:
Unsere Forschungs- und Entwicklungsteams sind weltweit im Einsatz und generieren Synergien aus unserem Expertenwissen und verwandten Fachdisziplinen. Wir stehen im internationalen Austausch mit unabhängigen Fachinstitutionen, Key Opinion Leadern und Multiplikatoren, um so Kooperations- und Wissensmanagement auf höchstem Niveau gewährleisten zu können. Im Rahmen dessen führen wir umfangreiche Forschungen durch, die kontinuierlich auf Kongressen in Form von Postern oder freien Vorträgen unserer Kooperationspartner sowie in Symposien und Workshops präsentiert und in namhaften wissenschaftlichen Fachzeitschriften veröffentlicht werden. Die größtenteils von unabhängigen Gutachtern bewerteten, evidenzbasierten Fachpublikationen, stellen wir Ihnen in dieser Datenbank zur Verfügung:
Wound care provides many challenges but none moreso than the management of high levels of exudate. The challenge is not only to be cost-effective and prevent maceration, but to improve the quality of life for the patient. Chronic wound fluid can be damaging to the wound healing process giving an added problem. This article examines the properties of Flivasorb® (Activa Healthcare), a wound dressing containing super absorbent polymer particles which not only absorbs high levels of exudate, but can retain the damaging particles in exudate, locking them inside the dressing.
A clinical pathway (CP) was developed and implemented to improve treatment outcomes for patients with venous leg ulcers. The CP and products (Rosidal® sys, Suprasorb® A, Suprasorb® P, and Suprasorb® C, Lohmann & Rauscher GmbH, Rengsdorf, Germany) were tested by case evaluation. Patients from the center were examined to determine his or her general condition, associated factors, wound type and stage, wound evolution, quality of life (QOL), treatment efficacy, and costs. Patients with venous leg ulceration (N = 20) were recruited to the clinical evaluation. Examination was performed upon presentation, and then at 2-week intervals for 12 weeks. The patients were then followed until ulcer closure. The outcome of the study group (SG) was compared to the results of a randomly selected patient control group (CG) at the center before implementing the clinical pathway. Statistic evaluation was performed using StatXact 5.0, double sided (α = 0.05) for paired and Wilcoxon test, and unpaired with Mann-Whitney (N = 20, [10/10]). After implementation, a statistically significant (P < 0.005) shorter period for ulcer closure was demonstrated for the SG when compared to previous treatment given to the CG. In the SG, 5/10 ulcers closed within 12 weeks versus 3/10 in the CG. An improvement in QOL was noted for the SG (P < 0.05 for the combined parameters, and P < 0.005 for pain), as well as cost savings (P < 0.05). The CP applied throughout the complete care chain improved quality of treatment outcomes and made effective use of resources and materials.